O-RAN-ALLIANCE
14.7.2022 17:07:08 CEST | Business Wire | Press release
O-RAN ALLIANCE:
52 O-RAN Specifications Published since March 2022
O-RAN ALLIANCE has published a new set of 52 specifications for open and intelligent RAN, as the first batch of the O-RAN Release 003 specifications. Among them there are 12 new titles including use cases for Massive MIMO and the R1 interface, E2 interface testing, O2dms interface, Acceleration Abstraction Layer, outdoor macro cell HW, and security specification of 3 different parts of the O-RAN Architecture.
“The O-RAN ALLIANCE has always taken security very seriously. We have recently converted the Security Focus Group into O-RAN’s 11th technical Work Group to allow even more intensive specification efforts in the field of security,” said Andre Fuetsch, Chairman of the O-RAN ALLIANCE and Chief Technology Officer of AT&T. “Security experts from the O-RAN ecosystem have been applying systematic threat analysis on different components of the O-RAN Architecture. Security is becoming an integral part of individual interface or function specifications and there is a security testing specification for proper verification. A systematic and transparent approach to security by the broad O-RAN ecosystem follows best practices seen in other parts of the network to ensure the best possible, most secure solutions.”
Another 40 technical documents have been updated with extensions and new features.
To learn more about the new and updated specifications, please read our web announcement . To access the O-RAN specifications, please visit our website .
6th Release of Open Software for the RAN – “F” – Delivered by the O-RAN Software Community
In June 2022, following on the half year release cycle, the O-RAN Software Community (OSC) published its 6th open software release dubbed "F". The F Release continues to improve the support for Traffic Steering and Network Slicing use cases, as well as the alignment with the latest O-RAN specifications.
Main features of the F release include:
- For O-Cloud, the OSC O-CLOUD platform implemented O2 DMS and IMS, and support of 3 types of resource pools (SIMPLEX, DUPLEX, and DUPLEX +) according to the O-RAN O-CLOUD specification
-
For Intelligence, the F release delivered:
- Implementation of A1-Policy & A1-EI functions according to O-RAN specifications
- Initial R1 interface support such as Data Management Exposure
- Update of the Near-RT RIC to support E2AP specification v2.0
- xApp framework for Python with support of the REST-based interface for E2 subscriptions
- For the radio protocol, new features include Intra-CU handover, Idle Mode Paging and HARQ framework in a new version
- The Service Management and Orchestration (SMO) added its management enhancement by supporting the Standard Defined Messages (StdDefine) over the O1/VES interface, while developing the framework for Network Slicing, and support for the O2 interface
- Tools and functions to provide the O-RAN deployment topology view for rApp and CNF deployment
"Congratulations to the team for continuously progressing at the pace of 2-release cycle per year since its inception in 2019," said Chih-Lin I, co-chair of O-RAN Technical Steering Committee, and Chief Scientist from China Mobile. "One of the key highlights from F release is the implementation of the O-CLOUD with multiple resources, which becomes the steppingstone to Service Management and Orchestration (SMO) xNF deployment for the G release."
“Ericsson continues to actively engage in the O-RAN ALLIANCE and O-RAN Software Community,” said Per Beming, VP Head of Standard & Industry Initiatives at Ericsson. “We recognise the potential for an ecosystem of multi-vendor rApps which support service providers in deploying, evolving, optimizing and automatically healing the RAN. We imagine a world in which simple multi-vendor rApps are used to build complex use cases and recognize the importance of the R1 interface in enabling this vision. As the main contributor to the Non-Realtime RIC project in OSC F release, Ericsson has focused on the challenges involved in exposing services over the R1 interface, in addition to elaborating an approach to rApp life cycle management.”
To deep-dive into the F release and to get the open software, please visit the O-RAN Software Community website .
1st Certificates Awarded in the O-RAN Certification and Badging Program by Asian OTICs
The first two O-RAN Certificates have been awarded, validating the establishment of the O-RAN Certification and Badging Program.
O-RAN ALLIANCE announced its Certification and Badging Program in June 2022, in cooperation with Open Testing and Integration Centers (OTIC). O-RAN Certification and Badging Program represents a comprehensive mechanism ensuring confidence in O-RAN solutions within the industry.
O-RAN certificates state that an equipment or function is conformant to O-RAN specifications, whereas O-RAN badges confirm interoperability or end-to-end functionality of an O-RAN solution.
O-RAN ALLIANCE maintains a Catalogue of O-RAN Certificates and Badges at its website .
The Asia & Pacific Open Test and Integration Center (OTIC) in China PRC issued the O-RAN Conformance Certification at the end of June 2022. The certification was awarded to an O-RU that fully meets the O-RAN WG4 Open Fronthaul (OFH) technical specifications, including the Control, User, and Synchronization plane (CUS-Plane) and the Management-plane (M-Plane). The complete process consisted of two phases, namely the pre-tests and the official verification, with all 31 test cases verified and passed.
Another O-RAN RU certification testing took place in the Auray OTIC and Security Lab. During the O-RAN Global PlugFest Spring 2022, the OTIC completed OFH conformance certification by conducting the required tests following the process and procedure specified by the O-RAN ALLIANCE. Auray OTIC and Security Lab also obtained TAF ISO/IEC 17025 approval for O-RAN test specifications and follows ISO/IEC 17065 to add independent peer viewer procedure.
Both awarded RUs are ready for commercial deployment for Tier one and other operators.
Upon approval by the O-RAN ALLIANCE, each OTIC provides collaborative, open, and impartial working environment to ensure consistency and quality of testing of O-RAN products and solutions.
All approved OTICs are fully ready to support the O-RAN Certification and Badging Program. Companies that want to apply for O-RAN Certificate or Badge may choose to contact any OTIC according to its specialization or region. Visit our website to see all available OTICs.
About O-RAN ALLIANCE
The O-RAN ALLIANCE is a world-wide community of more than 340 mobile operators, vendors, and research & academic institutions operating in the Radio Access Network (RAN) industry. As the RAN is an essential part of any mobile network, the O-RAN ALLIANCE’s mission is to re-shape the industry towards more intelligent, open, virtualized and fully interoperable mobile networks. The new O-RAN specifications enable a more competitive and vibrant RAN supplier ecosystem with faster innovation to improve user experience. O-RAN based mobile networks at the same time improve the efficiency of RAN deployments as well as operations by the mobile operators. To achieve this, the O-RAN ALLIANCE publishes new RAN specifications, releases open software for the RAN, and supports its members in integration and testing of their implementations.
For more information, please visit www.o-ran.org .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220714005600/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
